[The heart and the eosinophil].
The beneficial effects of polynuclear eosinophils (PE) are well known. However, under certain circumstances, PE can be harmful. The heart is a prime target for PE toxicity which is due to release of basic proteins by eosinophils including major basic protein, cationic protein, and peroxidase. The most common manifestation of PE toxicity is chronic parietal endocarditis (CPE) which regroups two entities: Loeffler's fibroplastic endocarditis and Davies' endomyocardial fibrosis. Loeffler's fibroplastic endocarditis occurs mainly in temperate climates. Patients present high, persistent eosinophil levels similar to those observed in essential hypereosinophilic syndrome (EHS) or Chusid syndrome. Davies' endomyocardial fibrosis occurs in tropical countries where eosinophilic helminthiasis are endemic. The incidence of eosinophilic myocarditis (EM) is low but probably underestimated. EM can be observed in any case involving PE and has been described in many cases of drug-induced atopy, in Churg and Strauss syndrome, and in EHS. The most common cause of death is short-term occurrence of cardiogenic shock or dilated hypokinetic cardiomyopathy. Some patients have been successfully treated by early, intensive corticosteroid therapy and/or heart transplantation. The nosological classification of EM and CPE remains controversial. The two disorders may form a continuum with CPE as the second phase. Other authors have suggested that EM and CPE result from the action of PE on two distinct targets, i.e. endothelial cells for EM and myocytes for CPE. In the future, it may be possible to identify subjects with a predisposition to PE-induced heart disease by studying of genes coding for interleukins (IL-5, IL-4, IL-3) and GM-CSF in the 5q31-q33 region of chromosome 5.
Service de Cardiologie, Hôpital d'Instruction des Armées Laveran, Marseille, France. jtouze@aol.com
J E
JE
Touze
L
L
Fourcade
P
P
Heno
B
B
Mafart
S
S
Mourot
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002423:Cause of Death; D002980:Climate; D004719:Endomyocardial Fibrosis / Q000145:classification / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy; D004804:Eosinophils / Q000276:immunology*; D020022:Genetic Predisposition to Disease / Q000276:immunology; D016027:Heart Transplantation; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000145:classification / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy; D015994:Incidence; D007958:Leukocyte Count; D013256:Steroids
D000893:Anti-Inflammatory Agents; D013256:Steroids
Le coeur et l'eosinophile.